An observational study in Cystic Fibrosis, sponsored by National Jewish Health. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-03-11.
Sponsored by National Jewish Health · Observational
This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.
1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.
This study's enrollment of 8 is below the median of 85 across 482 observational studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →National Jewish Health is the lead sponsor of 108 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients at National Jewish Health with Cystic Fibrosis who are eligible to enroll in Vertex's triple combination therapy expanded access program.
Exclusion Criteria:
Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
Drug: Triple combination therapy
Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
pulmonary function
FEV1 values.
Time frame: For a year post initiation of therapy.
CFQ-R score
cystic fibrosis questionnaire - revised has sections to measure pulmonary health and gastrointestinal health.
Time frame: For a year following the initiation of triple combination therapy.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Jewish Health